<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407001</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0691</org_study_id>
    <secondary_id>NCI-2018-00895</secondary_id>
    <secondary_id>2017-0691</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>R01CA195524</secondary_id>
    <nct_id>NCT03407001</nct_id>
  </id_info>
  <brief_title>Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis</brief_title>
  <official_title>Lesion Detection in Cirrhotic Patients With Contrast Enhanced Ultrasound and the Accuracy of Contrast Enhanced Ultrasound Li-RADS for Hepatocellular Carcinoma Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well contrast enhanced ultrasound with sulfur
      hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants
      with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are
      injected into a vein in order to help certain organs and tissues show up more clearly on
      scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver
      cancer compared to ultrasounds without contrast agent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the accuracy of contrast enhanced ultrasound (CEUS) utilizing contrast agent
      sulfur hexafluoride lipid-type A microspheres compared to B-mode non-contrast enhanced
      ultrasound for liver lesion detection, including hepatocellular carcinoma (HCC), in cirrhotic
      ultrasound (US) patients.

      SECONDARY OBJECTIVES:

      I. Determine the concordance of CEUS vs. contrast enhanced magnetic resonance imaging
      (CE-MRI) Liver Imaging Reporting and Data Systems (Li-Rads).

      OUTLINE:

      Within 30 days of routine MRI, participants undergo non-contrast ultrasound of the abdomen.
      Participants then receive Lumason intravenously (IV) and undergo contrast-enhanced ultrasound
      of the abdomen over 1 hour.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of contrast enhanced ultrasound (CEUS) with contrast agent sulfur hexafluoride lipid-type A microspheres and B-mode non-contrast enhanced ultrasound</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The study will estimate the sensitivity of ultrasound (US) and CEUS in patients with detectable lesions on magnetic resonance imaging (MRI). The analysis will be conducted at the patient level with a binary outcome of 0 if the patient has no detectable lesions and 1 if the patient has one or more detectable lesions. The study will use McNemar's test to compare US vs. CEUS in patients with any detectable lesions on MRI. The test assesses whether the two tests have equivalent marginal probabilities (i.e. probability of detecting at least one lesion with US and CEUS is equivalent). McNemar's test statistic depends only on patients where US and CEUS disagree.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of CEUS and contrast enhanced magnetic resonance imaging (CE-MRI) Liver Imaging Reporting and Data Systems (Li-Rads)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The study will assess the concordance between CEUS Li-Rads and MRI Li-Rads scoring results for each lesion using a multinomial logit random effects model. The study will summarize the characteristics (the size, location, vascularity and enhancement pattern) of lesions detected by only one imaging modality, stratified by imaging type.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Screening (US, CEUS, Lumason)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 30 days of routine MRI, participants undergo non-contrast ultrasound of the abdomen. Participants then receive Lumason IV and undergo contrast-enhanced ultrasound of the abdomen over 1 hour in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast-Enhanced Ultrasound</intervention_name>
    <description>Undergo CEUS</description>
    <arm_group_label>Screening (US, CEUS, Lumason)</arm_group_label>
    <other_name>CEUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfur Hexafluoride Lipid Microspheres</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Screening (US, CEUS, Lumason)</arm_group_label>
    <other_name>Lumason</other_name>
    <other_name>SF6 Lipid Microspheres</other_name>
    <other_name>Sulfur Hexafluoride Lipid-type A Microspheres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Undergo non-contrast US</description>
    <arm_group_label>Screening (US, CEUS, Lumason)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to provide written informed consent

          -  Diagnosis of cirrhosis based on one or more of the following: histology, US, computed
             tomography (CT) or MRI showing cirrhosis, +/- lesions seen on CE-MRI

        Exclusion Criteria:

          -  History of hypersensitivity to sulfur hexafluoride lipid microsphere components or to
             any of the inactive ingredients in Lumason

          -  Pregnant patients-excluded by history

          -  Pediatric patients, as pediatric cirrhosis is uncommon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ott Le</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ott Le</last_name>
    <phone>713-792-3673</phone>
    <email>ott.le@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ott Le</last_name>
      <phone>713-792-3673</phone>
    </contact>
    <investigator>
      <last_name>Ott Le</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

